Dry Eye SyndromesNCT02585648
Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome
A study testing Thealoz Duo Gel and Thealoz Duo eye drops and Thealoz Duo eye drops in people with Dry Eye Syndromes, run by Medical University of Vienna at 1 site in Austria.
Trial summary
Dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. Topically administered lubricants are the basis for treatment of this disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Dry Eye Syndromes
- What is being tested?
- Thealoz Duo Gel and Thealoz Duo eye drops and Thealoz Duo eye drops
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteAustria
- Study dates
- Feb 2016to Nov 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women aged over 18 years
- Signed and dated written informed consent.
- History of dry eye syndrome for at least 3 months
- Tear Break Up Time (BUT) ≤ 10 seconds or Schirmer I test ≤ 5 mm and ≥ 2mm
- OSDI ≥ 22
- Normal ophthalmic findings except dry eye syndrome
- No administration of topical lubricants 24 hours before the screening examination
Who cannot join
- Presence of an ocular pathology judged by the investigator as incompatible with the study.
- Any other clinical relevant ocular abnormality except DES.
- History of allergy, known hypersensitivity to one of the components: the administered medical device product, fluorescein or lissamine green
- History of known clinically relevant allergy
- Medical or surgical history judged by the investigator to be incompatible with the study participation (hepatic or renal insufficiency; all chronic severe organic disease: metabolic, endocrine, neoplastic, hematological disease; severe psychiatric illness, etc.).
- History of a recent acute illness with a recovery period within the 2 weeks before the inclusion visit (Day 0).
Show all 11Show fewer
- Pregnancy, lactation.
- Pre-menopausal woman who is not using a reliable birth control method (oral contraceptives or coil) or is not surgically sterilized.
- Participation in any high-speed or water-sports during the study without ocular protection (goggles or glasses).
- Subject unable to understand the study instructions or unlikely to comply with the study schedule and treatment.
- Participation in another clinical study in the 4 weeks before the start of the present study or at the same time as the present study.
Trial locations and contacts
1 site in 1 country.
Austria1 site
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, 1090
About this study
Dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. Topically administered lubricants are the basis for treatment of this disease.
Relief of symptoms in patients with moderate to severe dry eye disease is usually reached by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels.
- Conditions
- Dry Eye Syndromes
- Being tested
- Thealoz Duo Gel and Thealoz Duo eye drops, Thealoz Duo eye drops
- Medical subject headings
- Dry Eye Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thealoz Duo Gel and Thealoz Duo eye dropsDevice
Also called Intervention 1
Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
Thealoz Duo eye dropsDevice
Also called Intervention 2
Thealoz Duo eye drops during the day (4 to 6 drops per day)
| Study group | Role | What they receive |
|---|---|---|
| Patients with dry eye syndrome 1 | Experimental | 20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2 Receives: Device: Thealoz Duo Gel and Thealoz Duo eye drops; Device: Thealoz Duo eye drops |
| Patients with dry eye syndrome 2 | Experimental | 20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1 Receives: Device: Thealoz Duo Gel and Thealoz Duo eye drops; Device: Thealoz Duo eye drops |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient satisfaction when awakening (VAS)
Measured: 4 weeks
Secondary outcomes (6)
Quality of life
Measured: 4 weeks
Number of drops of Thealoz Duo instilled during the day (patient diary)
Measured: 4 weeks
Tear break up time
Measured: 4 weeks
Conjunctival and corneal staining
Measured: 4 weeks
Schirmer 1 Test
Measured: 4 weeks
OSDI questionnaire
Ocular Surface Disease Index Questionnaire
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2015 (estimated)
- Study startFeb 2016
- Primary completionMay 2016
- Study completionNov 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry Eye SyndromesStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gerhard Garhofer, Medical University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02585648
- Sponsor's protocol ID
- LT2258-PIV-0215
- Status last verified
- Mar 2017
- First submitted
- 26 Apr 2015
- Last updated
- 27 Mar 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome
- ClinicalTrials.gov ID
- NCT02585648
- Acronym / sponsor ID
- LT2258-PIV-0215
- Conditions
- Dry Eye Syndromes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Study start
- Feb 2016
- Primary completion
- May 2016 (actual)
- Study completion
- Nov 2016 (actual)
- First posted
- 23 Oct 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. Topically administered lubricants are the basis for treatment of this disease.
Relief of symptoms in patients with moderate to severe dry eye disease is usually reached by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with dry eye syndrome 1 | Experimental | Device: Thealoz Duo Gel and Thealoz Duo eye drops, Device: Thealoz Duo eye drops20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2 |
| Patients with dry eye syndrome 2 | Experimental | Device: Thealoz Duo Gel and Thealoz Duo eye drops, Device: Thealoz Duo eye drops20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Men and women aged over 18 years
- Signed and dated written informed consent.
- History of dry eye syndrome for at least 3 months
- Tear Break Up Time (BUT) ≤ 10 seconds or Schirmer I test ≤ 5 mm and ≥ 2mm
- OSDI ≥ 22
Key exclusion criteria (11 listed)
- Presence of an ocular pathology judged by the investigator as incompatible with the study.
- Any other clinical relevant ocular abnormality except DES.
- History of allergy, known hypersensitivity to one of the components: the administered medical device product, fluorescein or lissamine green
- History of known clinically relevant allergy
- Medical or surgical history judged by the investigator to be incompatible with the study participation (hepatic or renal insufficiency; all chronic severe organic disease: metabolic, endocrine, neoplastic, hematological disease; severe psychiatric illness, etc.).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thealoz Duo Gel and Thealoz Duo eye dropsAlso: Intervention 1Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day) | Device | Patients with dry eye syndrome 1, Patients with dry eye syndrome 2 |
| Thealoz Duo eye dropsAlso: Intervention 2Thealoz Duo eye drops during the day (4 to 6 drops per day) | Device | Patients with dry eye syndrome 1, Patients with dry eye syndrome 2 |
Primary outcome
Patient satisfaction when awakening (VAS)
Time frame: 4 weeks
6 secondary outcomes
Quality of life
Time frame: 4 weeks
Number of drops of Thealoz Duo instilled during the day (patient diary)
Time frame: 4 weeks
Tear break up time
Time frame: 4 weeks
Conjunctival and corneal staining
Time frame: 4 weeks
Schirmer 1 Test
Time frame: 4 weeks
OSDI questionnaire
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2017.
Related trials for Dry Eye Syndromes
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
The Pathogenesis and Natural History of Sjogren's Disease
Sjogren's Syndrome, Salivary Gland
Not yet recruitingPhase 2
Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments
Dry Eye Disease (DED), Graft-Versus-Host Disease(GVHD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thealoz Duo Gel and Thealoz Duo eye drops and Thealoz Duo eye drops in people with Dry Eye Syndromes, run by Medical University of Vienna at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient satisfaction when awakening (VAS) (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2017.